Cargando…

Serologic Response to Messenger RNA Coronavirus Disease 2019 Vaccines in Inflammatory Bowel Disease Patients Receiving Biologic Therapies

Detalles Bibliográficos
Autores principales:	Wong, Serre-Yu, Dixon, Rebekah, Martinez Pazos, Vicky, Gnjatic, Sacha, Colombel, Jean-Frederic, Cadwell, Ken
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	by the AGA Institute 2021
Materias:	Brief Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8055494/ https://www.ncbi.nlm.nih.gov/pubmed/33887219 http://dx.doi.org/10.1053/j.gastro.2021.04.025

Ejemplares similares

There was collusion: Microbes in inflammatory bowel disease
por: Wong, Serre-Yu, et al.
Publicado: (2018)

The role of gastrointestinal pathogens in inflammatory bowel disease: a systematic review
por: Axelrad, Jordan E., et al.
Publicado: (2021)

Coronavirus Disease 2019 Messenger RNA Vaccine Immunogenicity in Immunosuppressed Individuals
por: Collier, Ai-ris Y, et al.
Publicado: (2021)

Serologic Screening for Coronavirus Disease 2019 in Patients With Glomerular Disease
por: Turner-Stokes, Tabitha, et al.
Publicado: (2021)

Multidisciplinary diagnostic approach for fulminant myocarditis related to coronavirus disease 2019 messenger RNA vaccines: a case report
por: Fujii, Masayoshi, et al.
Publicado: (2023)

Immune parameters during anaphylaxis to messenger RNA coronavirus disease 2019 vaccines: Not the usual suspects?
por: de Chaisemartin, Luc, et al.
Publicado: (2022)

Effectiveness of Messenger RNA-1273 Vaccine Booster Against Coronavirus Disease 2019 in Immunocompetent Adults
por: Florea, Ana, et al.
Publicado: (2022)

Presence of Comorbidities Associated with Severe Coronavirus Infection in Patients with Inflammatory Bowel Disease
por: Parekh, Rajen, et al.
Publicado: (2021)

Serological response to vaccination against coronavirus disease-19 in patients with inflammatory bowel disease
por: Mathur, Akash, et al.
Publicado: (2023)

1163: BOTH VEDOLIZUMAB AND ANTI-TNF THERAPY ARE ASSOCIATED WITH ATTENUATION OF SEROLOGICAL AND NEUTRALIZING RESPONSES TO SARS-COV-2 INFECTION IN INFLAMMATORY BOWEL DISEASE
por: Wellens, Judith, et al.
Publicado: (2022)

Serological evaluation of patients with coronavirus disease-2019 in Daegu, South Korea
por: Park, Sunggyun, et al.
Publicado: (2022)

Anti-TNF Withdrawal in Inflammatory Bowel Disease
por: Torres, Joana, et al.
Publicado: (2016)

Evaluation of anaphylaxis risk by skin testing with coronavirus disease 2019 messenger RNA vaccines on patients with anaphylaxis
por: Pienkowski, Marek M., et al.
Publicado: (2022)

Myopericarditis after messenger RNA Coronavirus Disease 2019 Vaccination in Adolescents 12 to 18 Years of Age
por: Das, Bibhuti B., et al.
Publicado: (2021)

Coronavirus disease 2019 messenger RNA vaccine skin tests and serum histamine levels in allergic reactions
por: Kohli-Pamnani, Anita, et al.
Publicado: (2022)

Long-term evaluation of sperm parameters after coronavirus disease 2019 messenger ribonucleic acid vaccination
por: Diaz, Parris, et al.
Publicado: (2022)

Risk of myocarditis and pericarditis following coronavirus disease 2019 messenger RNA Vaccination—A nationwide study
por: Su, Wei-Ju, et al.
Publicado: (2023)

Clinical Characteristics and Outcomes of Coronavirus Disease 2019 Patients Who Received Compassionate-Use Leronlimab
por: Yang, Bryant, et al.
Publicado: (2020)

Serologic and Cytokine Signatures in Children With Multisystem Inflammatory Syndrome and Coronavirus Disease 2019
por: Lapp, Stacey A, et al.
Publicado: (2022)

Clinical Application of Serologic Testing for Coronavirus Disease 2019 in Contemporary Cardiovascular Practice
por: Damluji, Abdulla A., et al.
Publicado: (2021)

Virological and Serological Assessment of US Army Trainees Isolated for Coronavirus Disease 2019
por: Hakre, Shilpa, et al.
Publicado: (2022)

Disproportionality analysis of anaphylactic reactions after vaccination with messenger RNA coronavirus disease 2019 vaccines in the United States
por: Rodriguez-Nava, Guillermo, et al.
Publicado: (2021)

Utility and futility of skin testing to address concerns surrounding messenger RNA coronavirus disease 2019 vaccine reactions
por: Pitlick, Mitchell M., et al.
Publicado: (2022)

Acute pulmonary thromboembolism after messenger RNA vaccination against coronavirus disease 2019: A case report
por: Ishibashi, Yohei, et al.
Publicado: (2023)

Serological markers of inflammatory bowel disease
por: Kuna, Andrea Tešija
Publicado: (2013)

Multisystem Inflammation and Organ Dysfunction After BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccination
por: Kahn, Benjamin, et al.
Publicado: (2021)

Outcomes of allergic-type reactions after messenger RNA coronavirus disease 2019 vaccination at 3 military medical centers
por: St. Clair, Benjamin D., et al.
Publicado: (2022)

Antibody response to graded dosing of coronavirus disease 2019 messenger RNA vaccines after allergic reaction to first dose
por: Van Meerbeke, Sara W., et al.
Publicado: (2022)

Longitudinal Serological Analysis and Neutralizing Antibody Levels in Coronavirus Disease 2019 Convalescent Patients
por: Muecksch, Frauke, et al.
Publicado: (2020)

Differential Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Profiles After Allergic Reactions to Messenger RNA Coronavirus Disease 2019 Vaccine( )
por: Maron, Jenny S, et al.
Publicado: (2022)

Serologic celiac disease in patients with inflammatory bowel disease
por: Tavakkoli, Hamid, et al.
Publicado: (2012)

Inflammatory Bowel Disease Patients With Coronavirus Disease 2019: The Picture Is Taking Shape
por: Papa, Alfredo, et al.
Publicado: (2021)

Longitudinal Neutralizing and Functional Antibody Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Variants Following Messenger RNA Coronavirus Disease 2019 Vaccination
por: Chen, Xuemin, et al.
Publicado: (2023)

Suboptimal Response to Coronavirus Disease 2019 Messenger RNA Vaccines in Patients With Hematologic Malignancies: A Need for Vigilance in the Postmasking Era
por: Agha, Mounzer E, et al.
Publicado: (2021)

Immunogenicity and Reactogenicity of Messenger RNA Coronavirus Disease 2019 Vaccine Booster Administered by Intradermal or Intramuscular Route in Thai Older Adults
por: Assantachai, Prasert, et al.
Publicado: (2023)

Risk of Coronavirus Disease 2019 Messenger RNA Vaccination-Associated Myocarditis and Pericarditis – A Systematic Review of Population-Based Data
por: Lin, Yen-Ching, et al.
Publicado: (2023)

Coronavirus Disease 2019 Viremia, Serologies, and Clinical Course in a Case Series of Transplant Recipients
por: Christensen, Johanna, et al.
Publicado: (2020)

Clinical and serological findings in pregnant women and newborns: patterns of coronavirus disease 2019 placental histopathology
por: Conde, Thayana Camara, et al.
Publicado: (2023)

Clinical Features and Outcomes of Coronavirus Disease 2019 in Patients with Inflammatory Bowel Disease and Spondyloarthropathies
por: Tozlu, Mukaddes, et al.
Publicado: (2022)

Patients with inflammatory bowel disease are more hesitant about Coronavirus disease 2019 vaccination
por: Kwon, Hyuk Joon, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qejmnthkbpcsdpld4ieiik9ntq